June 30 CTN/ATTC Webinar: ED-Initiated Buprenorphine for OUD
The goal of the National Institute of Drug Abuse (NIDA) Clinical Trials Network/Addiction Technology Transfer Center (ATTC) webinar series is to help scholars and clinicians in the addiction field stay abreast of cutting edge science.
Please join us for our next joint webinar:
Emergency Department-Initiated Buprenorphine for Opioid Use Disorder
June 30, 2022 | 11:00am - 12:30pm (PT) | Register here
This webinar, presented by Gail D'Onofrio, MD (Yale School of Medicine), will focus on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. The opioid epidemic combined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with rising rates of fentanyl use. Dr. D'Onofrio will share data supporting the use of buprenorphine in the ED and discuss the consequences of not initiating treatment, barriers to implementation of ED buprenorphine, and components of successful integration of an ED program with community partnerships. She will also share current research by emergency physicians regarding innovative strategies like high-dose induction and use of an extended release 7-day formulation of buprenorphine.
- Evaluate at least 2 outcomes for opioid use disorder in patients receiving buprenorphine through the Emergency Department and discuss supporting evidence
- Identify at least 2 barriers and 2 solutions to initiating buprenorphine in the Emergency Department
- Apply at least 2 harm reduction strategies and components of the buprenorphine integration pathway
- Propose at least 2 innovative solutions for buprenorphine induction in the ED including different formulations of buprenorphine and high dose strategies
1.5 CME or CE credits available to those who attend the live event. Credit types include: CME (AMA PRA Category 1 CreditTM), PSY (APA), RN (ANCC), LMFT, LCSW, LPCC, LEP (CAMFT), RADT I/II, CADC-CAS, CADC I/II, CADC-CS, LAADC (CCAPP), CATC (ACCBC/CAADE), CAODC (CADTP), or generic certificate of attendance. For details about accreditation, please download our flyer.
Sponsored by the Northwest and Pacific Southwest Addiction Technology Transfer Centers (ATTCs) and the Western States Node of the NIDA Clinical Trials Network.